Consistently, either a single treatment of a PARP inhibitor or combined treatment with a CHK1 inhibitor was demonstrated to increase RS or further potentiate the increased RS in neuroblastoma cells with MYCN amplification [84], supporting the compatibility between PARP inhibitors and inhibitors of the ATR-CHK1 pathway for effectively inducing catastrophic cell death. The gene discussed is MYCN; the disease is neuroblastoma.